Pre-made Amatuximab biosimilar ( Whole mAb, anti-MSLN therapeutic antibody) - benchmark reference antibody
Cat No.: GMP-Bios-ab-020
Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb) is a biosimilar expressed by mammalian cell line as a benchmark reference therapeutic antibody for cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic).
Amatuximab (development code MORAb-009) is a chimeric monoclonal antibody designed for the treatment of cancer. It was developed by Morphotek, Inc. Amatuximab is a monoclonal antibody that binds to mesothelin (a protein that is made by some cancer cells) and stops the cells from dividing.
Delivery impact due to the Coronavirus Outbreak
With the COVID-19 outbreak in the world, many flights have been cancelled. In order for the customer to receive the goods properly, we use the FedEx Customized Freight (FCF) of Fedex which demands a higher fee. If the delivery fee is more expensive in your area, we will contact you by mail.
|Catalog No.||Package||Price(In USD)||Qty (Quantity)||Sum(In USD)|
|Products Name (INN Index)||Anti-MSLN therapeutic antibody (Pre-made Amatuximab biosimilar,Whole mAb)|
|Highest_Clin_Trial (Jan '20)||Phase-II|
|100% SI Structure||None|
|99% SI Structure||4f33:BA:DC:FE:HG/4f3f:BA|
|95-98% SI Structure||None|
|Companies||Eisai Co Ltd;Morphotek;National Cancer Institute (USA)|
|Conditions Discontinued||Pancreatic cancer;Solid tumours|